CUMULATIVE INDEX 1999

Volume 22

March FORENSIC PSYCHIATRY, pages 1-219 ADDICTIVE DISORDERS, pages 221-515 Tune

September BIPOLARITY: BEYOND CLASSIC MANIA, pages 517-711

December EMERGENCY PSYCHIATRY, pages 713–980

Note: Page numbers of article titles are in boldface type

Abstinence, and mortality, in alcoholics, 379-308

for dual-diagnosis patient, 340-341 Acamprosate (calcium

acetylhomotayrinate), for alcohol dependence, 415-416

Accusatory hallucinations, 162

Acute stress disorder, on psychiatric emergency service, in women 877-878

management of, 774

Addiction, abuse vs. dependence and,

brain reward concept of, 302-303

cellular and molecular aspects of, 306-

definition of, 302

drive theory of, 302

essential features of, 289

hallmark behavioral pattern in, 301

medical model of, 483

neural circuitry of, 302-303

imaging studies of, 304-305 neurobiology of, glutamate in, 308

serotonin in, 307-308

physical dependence in, 426 physician role in, 489-490

Addiction medicine specialty, physician, 500-501

Addiction prevention and treatment,

physician role in, 489-505 Addiction treatment, research studies on,

California, 497 cost benefit of, 496-498

Fortune 100 company, 497

Minnesota, 497-498

of abstinence-based method, 496

role of physicians in, advocacy for improvement of alcoholism treatment, 498-499

advocacy for treatment, 499-500

research on, 495-498

research studies on, 495-498

Addictive diseases, education and training in, 471-480

postgraduate, 481-488

requirements for diagnosing and treating, generalist physician, 502 physician specialist, 501-502

Addictive disorders, affective disorders with, 335

anxiety with, 334-335

comorbidity with, 290

cultural and social factors in, 253-273 alienation of youth gangs, 263

binge drinking or drugging as social norm, 257

community involvement in illicit drugs and, 258-261

community leadership and, 263

cultural values and national policy, 265-267

ghetto ethnography, 261-263

substance end-use communities, 261 substance-producing communities, 258-259

substance-trading communities, 259-

consequences to, 259-260 victimization in, 260-261

war on drugs and externalizing an internal problem, 263-265

welfare and poverty programs and, adverse effects of, 262–263

Addictive disorders (Continued) epidemiology of, 229–235, 481 for alcohol abuse and dependence, 229–233

for drug abuse and dependence, 333–338

genetics of, 289-299

heritability studies of genotype in, 291-292

in adolescents, 275-288

medical comorbidity with, 333

neurobiology of, 301–312

nosology and epidemiology of, 221-240, 222-228, 231-240

nosology of, DSM-III, 222-223 DSM-III-R, 223-225

DSM-IV, 227-228, 279-280 ICD-10, 225-227

pharmacotherapy for, 291

populations at risk for, immigrants, 255-256

refugees, 256

sociocultural settings and, 254–257 youth in industrialized societies, 254– 255

postgraduate education and training in, 481-488

barriers to effective, 482-483

psychiatric comorbidity with. See also Dual-diagnosis disorders. epidemiology of, 331–336

in homeless population, 332-333

role of physician in prevention and treatment of, 489–505

social interventions in, 267-270 antialcohol ordinances, local, 269-270

antigang programs, 269 health insurance equity for treatment,

minimum legal drinking age, 268–269 public education, 268

server training and, 267-268 vehicular legislation, 268

youth programs, 267 sociocultural settings for, child raising and culture, 256–257

poverty and affluence, 256 treatment of, cost-effectiveness and outcomes in, 344-345

twelve-step and mutual-help programs for, 425-446

Addictive drugs, neurobiologic effects of, 290–291

Adenylate cyclase, as marker for substance abuse, 296

ADEPT (Alcohol and Drug Education for Physician Training in Primary Care), 471

ADH. See Alcohol dehydrogenase (ADH).ADHD (attention deficit hyperactivity disorder), juvenile violence and, 74–75

Adjustment disorder, with depressed mood, 759-760

Adolescents, alcohol and drug use in, 254–257

bipolar disorder in, diagnosis of, 635–636

mania in, lithium for, 637

psychiatric emergencies in, 865–874. See also Children and adolescents, in psychiatric emergencies.

Advance directive, coerced community care and, 185

Affective disorders, addictive disorders with, 335

prevalence of, 755

substance-use disorder in, outcomes and, 346

Affective psychoses, phenomenology of, 741–742

treatment of, emergency, 749–750

Age, in alcohol abuse and dependence, 229, 232, 234–235 Aggression, in children and adolescents,

867–868 Agitated depression, 551, 553–555

anxiety in, 559-560 as mixed depression, 562

as mixed state, 554-556, 560 as mixed state and the problem of mel-

ancholia, 547-564 clinical forms of, 555-557

diagnostic criteria for, 557

excited, 555-556

inner agitation in, 559 manifestations, patient complaints, part-

ner reports of, 555 nonpsychotic, 555 psychotic, 555

restlessness in, 559 temperament and, 561

versus hysteroid dysphoria, 556

Agoraphobia, in emergency psychiatry, 770 Alcohol, intoxication from, 806–807 mechanism of action of, 303

Alcohol abuse and dependence, as selfmedication, 520

biologic response in, gender differences in, 245–246

comorbidity and, 235-238 psychiatric, 235-236

course of illness in, gender differences in, 247–248

epidemiology of, 229–233 heritability of, 292

in bipolar disorder, 611-612

lifetime prevalence of, age and, 229 demographic correlates of, 232–235 Epidemiologic Catchment Area study data for, 229–230, 232–235

gender and, 229-232

National Comorbidity Study findings, 229, 231–232, 234–235 National Longitudinal Alcohol Epidemiologic Survey findings, 229, 231–235

mania in, 613

medical comorbidity with, 333

medical consequences of, 352–358 cardiovascular, 354–355

central nervous system, 356–358 drug interactions, 358 gastrointestinal, 354

gender differences in, 246–247 gynecologic, 356

hematologic, 355-356 metabolic, 356

signs and symptoms of, 353-354 trauma, 358

neuroimaging in, 316–318. See also Neuroimaging.

brain changes, age-related and, 320 cerebral blood flow in, 316, 318 cerebral metabolic rate of glucose, 316,

in long-term use, 321-322 intoxication stage, 316-318 withdrawal stage, 318-319

pharmacological treatments for, opioid agonist maintenance, 401–402 prevalence of, lifetime, 229–232

psychiatric comorbidity with, 331–332 gender issues in, 333–334

treatment of, 232-233

Alcohol and cocaine dependence, coping and social skills training for, 447–470 Alcohol and drug dependence, economic

impact of, 491–492 pharmacologic treatment of, 401–423

pharmacologic treatment of, 401–423 physician roles in, educational training, 494–495

in treatment, research studies on, 495-498

intervention, 493

physical examination, 492–493 prevention, 494–495

referral, 494

risk assessment, 493 support of recovery, 494

prevalence of, in families, 493 in general population, 490

in medical population, 491 in treatment populations, 490 in workplace population, 491

Alcohol and Drug Education for Physician Training in Primary Care (ADEPT), 471

Alcohol dehydrogenase (ADH), in alcohol metabolism, gender differences in, 246

genetic differences in, 296-297

Alcoholic myopathy, 358

Alcoholic patients, relapse prevention in, Acamprosate, 415–416

alcohol-sensitizing agents in, 412–414 medications for, 412–416 conclusions on, 416

opioidergic agents in, 414–415 serotonergic agents in, 415

Alcoholics Anonymous (AA), attendance and health care costs, 434

for dual-diagnosis patient, 342-343 growth and spread of, 428, 435

origin of, 427 research on, 430-434

effectiveness of drug therapy versus, 430–431

involvement versus attendance in, 431–432

prior involvement in, 432-433 Project MATCH and, 431-432, 434, 438

Alcoholism, genetics of, neurochemical markers in, 295–296

heredity and, gender differences in, 247 medical consequences of, mortality from, 374

mortality in, 371–373 abstinence and, 379–380

comorbidity and, 377–378 gender and, 378

predictors of, 373-375 race and, 378

tobacco use in, 375–376 underestimation of, 376–377

mortality risks in, and effects of abstinence and treatment, **371–383** prevalence of, 372

treatment of, role of physicians in, 498–

Alcohol-withdrawal syndrome, management of, on emergency

service, 806–807 Amantadine, for cocaine dependence treatment, 418

Ambulatory crisis care, 729

Americans with Disabilities Act, application to psychiatric disa

application to psychiatric disability, role of psychiatrist in, 149 areas covered by, 147–148

confidentiality and, conditions for psychiatric evaluation and, 156

during job application, 155–156 definition of disability in, 149

essential job functions and, 152 psychiatric disability and

danger and direct threat and, 154–155 reasonable accommodations for, 152–

assessment and implementation of, 152–154 employee obligation to request, 154 Americans with Disabilities Act (Continued) treatment and, 153

psychiatric disability requirements DSM-IV diagnosable mental illness, 149–150

limitation of major life activity and,

case law decisions, 151-152 duration of, 150

interpretation of, 151-152

Title I and, 149

exemptions to, direct threat, 148, 154-155

undue hardship, 149 violence risk and, 148

Amphetamines, mechanism of action of, 303

Anticonvulsants, in bipolar disorder, 596–598

versus lithium, in mixed disorders, 621 in rapid-cycling bipolar disorders, 621

Antidepressants, effect on racing and crowded thoughts, 558

for anxiety disorders, 578 for anxious depression, 560

for cocaine dependence treatment, 418–

for dual-diagnosis patient, 340, 342 for elderly bipolar patient, 657

for rapid-cycling bipolar disorder induction, 590-592

for smoking cessation, 411

switch into hypomania/mania with, 519, 520, 526-527, 532, 572, 590-592 in depressed patient with cyclothymic

temperament, 695–696 Antipsychotics, atypical, for agitation and aggression, 797–798

for mania, in emergency department, 841

Antisocial personality disorder, substance abuse and, gender differences in, 244 versus antisocial behavior, 857

Antisocial personality disorder patient, in emergency department, psychiatrist anger toward, 921

psychodynamic considerations of, 920 secondary goals of, 920 suicidal ideation in, 915

Anxiety, addictive disorders with, 334–335 and substance use disorders, in adolescence, 281

in agitated depression, 559-560

in depressive disorders, neuroleptics versus antidepressants for, 560-561

in emergency department, evaluation of,

medical illness- or substance-induced, 844-845 pharmacotherapy for, 846-847 in major depressive episode, 560 manifestation of, in withdrawal syn-

dromes, 813

Anxiety disorder(s)-bipolar comorbidity, hypomania and, temporal

relationships with, 571–574 in bipolar II disorder, 567–568

in child or adolescent, emergency department handling of, 871

violence in, 794–795 Anxiety disorder(s)-bipolar disorder comorbidity, 532, 697

clinical study support of, 566–567 cyclothymic/hyperthymic temperaments

and, 575
epidemiologic evidence of, 565–583, 566
impact on course of disorders, 567–568

impact on course of disorders, 567–568 in bipolar II disorder, 567–568 interpersonal sensitivity in 574–576–577

interpersonal sensitivity in, 574, 576–577 lifetime, 576

obsessive-compulsive disorder, 568–570 panic disorder, 571–574 social phobia, 567–568, 570, 572–573

temporal relationships in, 571-574 treatment of, 578-579

Anxiety syndrome(s) classification of, 766–767

in emergency psychiatry, 766–775 as response to stress, 770–771

assessment of, 767–769 classification of, 766–767

differential diagnosis of, 770 management and disposition of, 772–

775 manifestations of, 766

medical illness- or substance-induced, 771-772

primary, 769-770 secondary, 771-772

Assault, in health care, location of, 924–925 victim profession and, 925–926

on clinician, 860-861

patient characteristics predictive of, 927–929

prevention of, assessment of violent patient in, 931–932 laboratory studies in, 930–931

Assaultive patient, pharmacotherapy for,

strategies for handling, administration, 934

clinician education, 933-934 staff, 935

verbal and physical, 932–933
Assertiveness training, in cocaine-specific

coping skills training, 464 Atabuse. See Disulfiram (Atabuse).

Attention, impairment of, in delirium, 736-737

Attention deficit hyperactivity disorder (ADHD), juvenile violence and, 74–75
Attitude, addiction and, 336–337
Atypical depression, borderline personality disorder label in, 575
cyclothymia in, 575
interpersonal sensitivity in, 574, 576–578 subsets of, 574–578

Behavior therapy, for sex offenders, 120 Behavioral responses, in cocaine-specific coping skills training, 465 Beliefs, clinician, in victimized woman

interaction, 888

cultural, and war on drugs, 265 Benzodiazepines, dual-diagnosis patient and, 342

for anxiety, in emergency department, 846

for sedative-hypnotic withdrawal syndromes, 811

for substance abuse, 622 withdrawal from, 739

Bereavement, traumatic, in relatives of homicides, 901–902 in survivors of disaster, 900–902

Best interests standards, right to refuse psychiatric treatment and, 179

Bias, clinician, in victimized woman interaction, 888

Binge drinking, as social norm, 257–258 Binge drugging, as social norm, 257–258

Bipolar disorder, anxiety disorder comorbidity in, 565–583, 697 chronobiologic factors in, 677–678 clinical presentation of, as panic disor-

der, 696-697 comorbidity in, 532, 699

course of, social support and, 676–677 functional impairment in, 675–676 in adolescents, diagnosis of, 635–636

in children, 629-647

assessment of, 635-636

clinical rating scales in, 635–636 structured and semistructured interviews in, 635

clinical characteristics of, 632-634

diagnosis of, 630-631 differential diagnosis of, 634-635

historical overview, 629–631 treatment studies of, 636–638

carbamazepine, 637 divalproex sodium, 637

gabapentin, 638 lamotrigine, 638

lithium, 637 versus adults, 632, 636

in primary care

comorbidity in, 699 diagnostic formulation in, 699

management of, 700

screening for, 698–699 therapeutic alliance in, 699

therapeutic alliance in, 699 treatment plan formulation in, 699– 700

mixed. See Mixed states.

neuroimaging in, in elderly manic patients, 655–656

nosology of, 668

obsessive-compulsive disorder in, 568-570

onset of, in children *versus* adults, 632 panic disorder in, 571–574, 578 pharmacotherapy for, clozapine in, 638

in children versus adults, 636–637 noncompliance with, 678–679 risperidone in, 638

presentation of, as refractory depression with atypical features, 697–698

prevalence of, in drug *versus* alcohol abusers, 613

psychosocial interventions for, **675–688** psychosocial stressors in, 676–677 relapse in, causes of, 676–677, 682

social phobia in, 567-568, 570, 572-574, 578

substance-use disorders and, 813 Bipolar I 1/2 disorder, depression with protracted hypomania in, 521–522

Bipolar I disorder, suicidal behavior in, 668–670

versus bipolar II, 518

Bipolar II 1/2 disorder, cyclothymic depression in, 524–526

Bipolar II disorder, 522–524 and suicidal behavior, 667–673 anxiety disorders in, 578–579

comorbidity in, panic disorder in, 570 social phobia disorder in, 567–568

depression with hypomania in, 522-524 mania in, 520

misdiagnosis of, 670–672 obsessive compulsive disorder

obsessive compulsive disorder in, 568–570

prevalence of, 700-701

Bipolar III 1/2 disorder, stimulant abuse and, 527

Bipolar III disorder, hypomania in, antidepressant-associated, 519, 526–527

Bipolar IV disorder, hyperthymic depression, 528–531

Bipolar spectrum. See also named, e.g. Bipolar I disorder.

bipolar I, 519-521 bipolar II, 522-524

bipolar II 1/2, 524-526

bipolar III, 526-527

Bipolar spectrum (Continued) bipolar III 1/2, 527–528 bipolar IV, 529–531 evolving, 517–534 from Kraepelin to DSM-V, 517–519 prototypes I, II, III, IV, 517–534 Bipolarity, in children, 629–647

in depression, in family practice setting, 689–703

temperamental traits in, 694–695 Bipolarity in children. See also Bipolar disorder, in children; Mania, in children.

Borderline personality disorder (BPD). See also *Personality disorder*. as label in atypical depression, 575 bipolar II disorder *versus*, 524 depression in, 762

in emergency psychiatry, 762 in women, in emergency department,

treatment of, 884–886 pharmacotherapy for, 886–887 psychiatric emergency service role in, 885

Borderline personality disorder (BPD) patient, in emergency department, suicidal ideation in, 915–916

Boundaries, in psychotherapy, crossing of, 44-45

guidelines for, 31–32 principles underlying, 32–33 in sexual harassment treatment, 143 therapist-patient sex and, 31–33, 39–45 violation of, identification and prevention of, 44–45

progressive, 39–43 Brain reward, as concept of addiction,

302–303 thresholds of, with long-term drug use, 305–306

Bromocriptine, for cocaine dependence treatment, 417–418

Buprenorphine, for cocaine addiction, 308 neuroimaging studies and, 325 for cocaine dependence treatment, 420

for comorbid cocaine and opioid dependence, 417

for opiate detoxification, on emergency service, 810

for opioid dependence, 406, 408 Buprenorphine hydrochloride, for cocaine and opiate dependence, 808

Bupropion, for cocaine dependence treatment, 418

for dementia, in emergency department, 836–837

for smoking cessation, 411 in rapid-cycling bipolar disorder, 590, 598 Burch v Coca-Cola Co, psychiatric disability and Americans with Disability Act, 150–151

Burlington Industries Inc. v Ellerti, sexual harrassment, 136

Buspirone, for anxiety, in emergency department, 846–847

Calcium acetylhomotayrinate (Acamprosate), for alcohol dependence, 415–416

Calcium-channel blockers, in rapid-cycling bipolar disorder, 598

Carbamazepine, for cocaine dependence treatment, 419–420 for violent juvenile, 79–80

in bipolar disorder, 622 noncompliance with, 678–679

in cocaine-affective disorder comorbidity, 622

in elderly, as maintenance therapy, for mania, 658

in acute mania, 657 in mania, 660

in mania, in children and adolescents, 638

in rapid-cycling and mixed mania, 621-622

in rapid-cycling bipolar disorder, 596–597

with lithium, 597 Cardiovascular disorders, with alcohol use, 354–355

CEA. See Cost-effectiveness analysis (CEA). Cerebral blood flow, neuroimaging of, 315–316, 318

Cerebral metabolic rate of glucose, 315–316, 318

Cerebral vascular accident, in alcoholism, 354

CET. See Cue-exposure training (CET). Childhood sexual abuse, dissociative

identity disorder and, 4–5 false memory of, 3–4 juvenile violence and, 77

sexual harrassment evaluation and, 138 Children and adolescents. See also *Bipolar*

disorder, in children; Mania, in children. bipolar disorders in, 629-647 psychiatric emergencies in, 865-874 agitation and violence, 867 anxiety disorders, 871

conversion symptoms, 871 eating disorders, 871–872 epidemiology of, 865 fire setting, 872

general principles in, 865–866 physical abuse or neglect, 869–870 psychosis, 868–869 runaways, 873 sexual abuse or rape, 870–871 substance abuse, 872 suicide, 866–867 suicide threats or attempts, 866–867 treatment and disposition planning for, 873–874

Circadian rhythms, social cues and, 677-678

Cirrhosis, alcoholic, 354 mortality from, 374, 375 Clinician safety, **923–940**

Clonidine, for opiate withdrawal, on emergency service, 809 for opioid detoxification, 403 in opioid withdrawal, 407–408 with naltrexone, in detoxification, 407– 408

Clonidine-naltrexone combination, for opiate detoxification, on emergency service, 809–810

Clozapine, for bipolar disorder, 638 for schizophrenia, emergency treatment of, 748–749

Cocaine, biologic response to, gender differences in, 246 cellular and molecular aspects of, 307 mechanism of action of, 304 neurochemical effects of, 416–417

Cocaine abusers, cyclothymia in, 611, 613 Cocaine intoxication, in emergency services, psychosis in *versus* primary psychotic disorders, 808 signs of, 807–808

Cocaine use and addiction, medical complications with, 363–364 acute renal failure, 365 cardiac, 364 gender differences in, 247 intestinal ischemia, 365

> neurologic, 363-364 perforated nasal septae, 365

perforated nasal septae pulmonary, 365

neuroimaging of, cerebral metabolic rate for glucose in, 324–325 in intoxication stage, 324 in withdrawal stage, 324–325 regional cerebral blood flow in, 324– 325

treatment response in, 325 nondopamine strategies in, 308–309 relapse prevention in, antidepressants for, 418–419 buprenorphine for, 420 carbamazepine for, 419–420 dopaminergic medications for, 417–418

medications for, 416-421, 420-421 treatment response in, factors in, 421

withdrawal in, 416-417, 421

Cocaine-affective disorder comorbidity, carbamazepine in, 622 Cocaine-alcohol dependence, 808

Cocaine-arconol dependence, 808
Cocaine-specific coping skills training
(CSCST), assessment in, Cocaine
Negative Consequences Checklist
in, 462

Cocaine-Related Assessment of Coping Skills, 460-462 Cocaine-Specific Skills Test in, 460 high risk situations in, 461-462 Cocaine High Risk Situations Survey

and, 460

effectiveness of, 466

future of, 467 in treatment, formats for, 462–463 menu of coping skills for, 465–466 overview and rationale for, 462–463 specific session modules for, 463–464

Codependence, 337
Coerced treatment. See also under
Community treatment.

in community, 183–196

Cognitive dysfunction, manic syndromeassociated, 651

Cognitive responses, in cocaine-specific coping skills training, 465
Cognitive therapy, for sex offenders, 120

Cognitive-behavioral therapy (CBT), for additive disorders, in adolescents, 285–286

in alcoholism treatment, 431–432 Command hallucinations, content of, 162 dangerousness and, 162

Commitment statutes, outpatient, 184 Community psychiatric emergency service(s), ambulatory crisis care, 729 crisis respite and residential care in, con-

troversies about, 726 for special populations, 725 role and outcomes of, 725–726

mobile response, 726–729
Community treatment, coerced, 183–194
clinical guidelines for, 193
clinician liability fear, 191–192
conditional release and, 184
for insanity acquittees, 188–189
criticisms of, 189–191

effectiveness of, 187–188 for continuity of care, 192–193 predicted deterioration standard and, 192–193

forced medication issue and, 190–191 frequency of use, 187 guardianship and, 184–185 in practice, 187–189, 187–192 informal procedures for, 185–187 variations on, 186–187 judicially mandated, 183–185 lack of resources and procedural protections for, 189

Community treatment (Continued) loss of autonomy in, 192

outpatient committment statutes and, 184

parens patriae power and, 189 predicted deterioration standard and, 190

recommendations for, 193–194 research studies of, 187–189 resistance from community clinicians, 191–192

right to health and obligation to preserve health and, 192 substantive criteria for, 184

theoretic issues in, 192 Comorbidity, anxiety disorders-bipolar disorder, 565–583. See also Anxiety disorder(s)-bipolar disorder comorbidity.

definition of, 565 effect on alcoholism mortality, 377–378 in bipolar disorder, 532, 568–570, 578–

579, **609–627**, 699

in cocaine dependence, 419, 611, 613, 622 in mixed states, 537-538

of violence and mental disorders, 790-791

overview of, 331-349

psychiatric, victimization and violence with, 245

with alcohol abuse and dependence, 235–238

with drug abuse and dependence, 238 with substance abuse, gender differences in, 243–245

Competence, definition of, in emergency department, 852

determination of, 852-853

Competency, for voluntary hospitalization, Zinermon v Burch, 204–205

in psychiatric treatment refusal, assessment of, 177 rights-driven *versus* treatment-driven

approaches to, 178 to plead guilty or waive right to coun-

sel, Godinez v Moran, 203–204 Compliance. See Medication compliance.

Conduct disorder, juvenile violence and, 74–75

treatment of, 79 Confidentiality, Americans with

Disabilities Act and, 155–156 in sexual harrassment treatment, 143

Consent to treatment, in emergency department, competence and, 852–853

proxy by next of kin, 853 Continuing medical education, in addiction, 478

Conversion symptoms, in child or adolescent, emergency department handling of, 871 Coping and social skills training (CSST), client characteristics and, 448–450 cognitive impairment, 449 cue reactivity, 449–450

denial, 449

personality disorders, 449 cue-exposure training in, 449

for alcohol abuse treatment, 451-459 assessment for, 451-453

cue reactivity in, 451–452 behavioral role playing in, 453–454 communication skills training in, 453

coping-skills assessment in, 451 cue exposure training, with urge-specific coping skills, 455–459

drinking triggers interview in, 452–453 effectiveness of, 465–466

introduction and rationale session in, 4455–456

specific session models, 455 therapist modeling in, 453 for alcohol and cocaine dependence,

447-470 for cocaine users, 459-465. See also Co-

caine-specific coping skills training (CSCST).

settings for, group, 450 home, intersession homework assignments and, 450–451

individual, 450 Cost, of addictive disorders, 491–492

of alcohol abuse and dependence, 491–492

of emergency services, psychiatric emergencies and, 716

Cost benefit, of addiction treatment, 496–499

Cost-effectiveness, and outcomes, in addictive disorders treatment, 344–345 of substance abuse services, 385–400

Cost-effectiveness analysis (CEA), description of, 385

of substance abuse services. See Substance abuse services, cost-effectiveness analysis of.

purpose of, 386 Costs, health care, Alcoholics Anonymous attendance and, 434

Countertransference, in therapist-patient sex, 35–39

in victimized woman-provider interaction, 888–889

Criminal justice system, psychiatric patients and, 199–204

Criminal responsibility, malingered psychosis and, 169–170

Crowded thoughts, 558. See also Flight of ideas; Racing thoughts.

Cue reactivity, of alcohol users, assessment of, 451–452

Cue-exposure training (CET), in alcohol abuse treatment, beverage exposure in, 457 imaginary scene exposure in, 457–458 introduction and rationale in, 456–457 urge-coping skills in, 458–459

application of, 458 with urge-specific coping skills, 455-459

in coping and social skills training, 449 Culture, Supreme Court and, 197–198 Cyclothymia, cocaine abuse comorbidity in, 611, 613

Cyclothymic depression, hypomania in, 524–526

524–526 Cyclothymic temperament, criteria for, in bipolar disorder, 695 in atypical depression, 575 mixed states in, 561 rapid cycling in, 594

Cyproterone, for sex offenders, 122

Dangerousness, as result of severe mental

illness, 53–54 imminence of, determination of, 54–55 for protective disclosure, 54–55 retention of insanity acquittee for, 202–

203
Debriefing, elements in, 906
of survivors of disaster, 906–907

Decriminalization, of illicit substances, 26–267

Delirium, in alcohol-withdrawal, 807 in emergency department, acute treat-

ment of, 831-833 anticholinergic, 827

characterization of, 825-826

criteria for, 826

differential diagnosis and evaluation of, 827-831

EEG for, 831

laboratory studies of, 831

mental status examination findings, 826

onset of, 826-827

pharmacologic treatment of, 832-833 risk factors for, 827, 830-832

Delusional disorders, psychosis in, treatment of, 751

Delusions, definition of, 161

development of, 165 genuineness of, assessment for, 165

in malingerers, 161–162 in schizophrenia, 740–741

persecutory, 161

Dementia, in emergency department, differential diagnosis and evaluation of, 833–836 history and presentation of, 833 pharmacologic treatment of, 836–837 treatment of, acute, 836–837 suspicion for, 830

versus pseudodementia, 759

Dementia with Lewy bodies, in emergency department, treatment of, 834

Dependence, substance, 302

Depression. See also named, e.g. Atypical depression.

and substance use disorders, 813 gender differences in, 243–244 in adolescents, 281

anxiety and insomnia with, treatment of, 844

atypical, 574-578

bipolarity in, in children, 634

in family practice setting, 689–703 cyclothymic, hypomania in, 524–526 from medications, 842–843

hyperthymic, 528–531

hypomania and, 522–524 antidepressant-induced, 695–696 protracted, 521–522

in cocaine-specific coping skills training, 464

in elderly, conversion to bipolarity, 652-653

in emergency department, medical causes of, 843

treatment of, 843 in mixed states, 543

in primary care, 690-691

structured interview for, 690 psychotic, emergency treatment of, 750 reduction of, nervous system activity in,

seasonal, 532

treatment of, response to, 690

with anxiety, 762

with cyclothymia, 668

with flight of ideas, in Kraepelin, 550-551

Depressive reaction, concept of, 549 Depressive syndromes, in emergency

psychiatry, as response to stressful event, 759–760

assessment of, 757–758

classification of, 757

clinical presentation of, 756–757 comorbid with psychiatric disorders, 761–762

management and disposition of, 762-764

medically induced, 760-761

medication- or substance-induced, 760–761

outpatient referral for, 763-764 primary, 758-759

Desipramine, for cocaine dependence treatment, 418–419

Detoxification, pharmacotherapy for, 341 Dexamethasone suppression test (DST), im mixed states, 539

Dialectical behavioral therapy (DBT), for borderline personality disorder, 885

Diaster relief workers, post-traumatic stress disorder in. 900

traumatization of, intervention in, 906 Difficult Temperament Index, in classification of adolescent alcoholics,

Disinhibition syndromes, in old age, with mania, 653-654, 661

with neurologic disorders, 654 Disorganization, in schizophrenia, 741 Disorientation, in delirium, 737

Displacement, of survivors of disaster, psychological reaction to, 902-903 Dissociative identity disorder, childhood

sexual abuse and, 4-5

Disulfiram (Atabuse), for alcohol dependence, 412-414 inhibition of alcohol dehydrogenase and,

296-297 side effects and toxicity of, 413

Divalproex, for bipolar disorder, agitation in, 750

Divalproex sodium, in bipolar disorder, in children, 637

in mania, in adults, 637 in children and adolescents, 637 in mixed states, 541

Dopamine depletion hypothesis, for cocaine withdrawal symptoms, 417, 420-421

Dopamine neurotransmission, as target for drugs of abuse, 303

Dopamine system, in addiction, 302-303 Droperidol, for agitation and aggression,

in substance ingestion or withdrawal, 746-747

Drug abuse and dependence, comorbitidy and, depression, 238

medical comorbidity with, 333 Drug Abuse Warning Network (DAWN)

survey, 804-805 Drug abuse/dependence. See Substance abuse disorder(s)-bipolar disorder

comorbidity. Drug interactions, with alcohol use, 358 Drug use and addiction, mortality from,

Drug use and dependence, psychiatric comorbidity with, 331-332

Drugs of abuse, long-term use of, neurophysiologic chances with,

mechanisms of action for, 303-304 Dual-diagnosis disorders, 812-814. See also Comorbidity.

management of, 336-337 Dual-diagnosis patient, Alcoholics Anonymous for, 342-343 assessment of, 337-338

collaboration in, issues in medical and nonmedical, 343-344 triangular dynamics in, 343-344

medication guidelines for, 340-343

stabilization of, 338-340 intensity of care for, 338-339

outcomes and, 339-340 Patient Placement Criteria and, 338-339 sequential treatment of, 339

twelve-step programs for, 433-434 medication issue in, 439-440

Duty of care, Helling v Carey and, 11 Duty to protect third party, 49-60 as moral duty, 50

Boynton v Burglass and, 50

from violent or homicidal behavior, against specific, identifiable potential victims, 55-57

as result of severe mental illness, 53 ethics of protective disclosure and, 57 failure to hospitalize and, 53-54 imminence of danger and, 54-55 risk assessment and management in, 51-52

Tarasoff v Regents of University of California and, 1-2, 5-6 wrongful discharge and, 53

zone of danger rule and, 56-57 in emergency department, 858-859

Tarasoff Principle and, 49-50 Tarasoff v Regents of University of California and, 1-2, 5-6

Dysthymic disorder, characteristics of, 759 in emergency psychiatry, 759

Eating disorders, in child or adolescent, emergency department handling of, 871-872

Education and training, in addictive diseases, 471-480. See also Postgraduate training and training. continuing education, 489 faculty development for, 478-479 of physician, 471-472 residency training, 477-478 undergraduate medical education, 473-477 clinical, 475-477

preclinical, 473-475

Elderly, electroconvulsive therapy in, 661 women, victimization of, 880

Electroconvulsive therapy (ECT), comparison with lithium, in mixed states, 541-542

in depression, psychotic, 750 in elderly, 661 in mania and depression, 552 in rapid-cycling bipolar disorder, 599 Emergency, definition of, 713

Emergency department, differential diagnosis in, 825-847

Emergency petitions, in emergency department, by police officers, 854-855

for danger to self or others, 855-856 Emergency psychiatry, fellowships in, 951 residency programs in, 943 training issues in, 941-954 Epidemiologic Catchment Area study

(ECA), and gender differences in

substance use, 241

ERISA, malpractice liability and, 18 restrictions on health care and, McGann v H&H Music Company, 19-20 Metropolitan Life Insurance Company v Massachusetts, 19-217

Shaw v Delta Air Lines Inc., 19 ERISA managed care plans, exemption from liability and, for breach of professional standard of care, 25

liability exemption of, for restriction of care, 18-19

mental health benefits and, 19-21 restrictions causing harm to patients, 23-28

Andrews-Clarke v Travelers Insurance Company, 26-27

Corcoran v United Health Care, Inc., 25 Dukes v US Health Care, Inc., 26-27 wrong without remedy, 25 utilization review and liability for sui-

cide and, 21-22

Erotomanics, dangerous behavior of, 93 stalking by, 86

Expressed emotion (EE), in family members, relapse and, 677, 682

False memories, source and origin of,

False memory syndrome (FMS), 3-4 False victimization syndrome, 87 Family focused treatment (FFT), in bipolar disorder, 684-685

Family history, in mixed states, 539 mania and, in old age, 652-653 rapid-cycling bipolar disorder and, 594-595

Family practice, psychiatric training in, 689-690

Family practice mood disorder clinic, DSM-IV diagnoses in, 691-692

Family therapy, for additive disorders, in adolescents, 285-286

Faragher v Boca, sexual harrassment, 136 FFT (family focused treatment), in bipolar disorder, 684-685

Fire setting, by child or adolescent, emergency department handling of, 872-873

Flight of ideas. See also Crowded thoughts; Racing thoughts. in agitated depression, 560

versus racing thoughts, 557-558

Flumazenil, for sedative-hypnotic withdrawal syndromes, 811-812 Flutamide, for sex offenders, 122

Folstein Mini-Mental Status Examination. in emergency psychiatric assessment, 823-824, 835

Forensic psychiatric issues. See also Legal

in emergency department, 851-864 Foucha v Louisiana, retention of insanity acquittee, 202-203

sex offenders and, 114 Functional magnetic resonance imaging (fMRI), of neural circuitry of addiction, 305

Gabapentin, for bipolar disorder, 622 in children, adverse behavior with, 638 in elderly, for mania, 660-661

Gastrointestinal disturbances, with alcohol use, 354

Gender, in alcohol abuse and dependence, 229-234, 237

psychiatric comorbidity with, 333-334 in substance use disorders, 241-252 mortality in alcoholism and, 378

substance use and, biologic response to, 245-246

course of illness in, 247-248 heredity patterns in, 247 medical consequences of, 246-47 psychiatric comorbidity, 243-245 social issues in, 243 treatment of, 248-249

tobacco smoking and, and mortality among alcoholics, 375-376

Generalized anxiety disorder, in emergency psychiatry, 770 management of, 774

sexual harrassment and, 141 Genetics, in bipolar I and bipolar II disorders, 667

in bipolar II-panic disorder comorbidity, 570

Glutamate, in neurobiology, of addiction,

Godinez v Moran, competency to plead guilty or waive right to counsel, 203-204

Graduate medical education training, in addiction, advanced fellowship training and, 487 attitudinal base in, 466 curriculum content, 484-485 objective of, 483-484 specific knowledge base in, 484-485 specific skills base in, 485-486 Guardianship, coerced community

treatment and, 184-185

Gynecologic disturbances, in alcoholism, 356

Hallucination(s), accusatory, 162 auditory, attitudes of psychiatric inpatients toward, 162-163 characteristics of, 161-162 content of, 163 types of, 162 in delirium, 737

malingered, areas of inquiry in, 161 auditory, 161-163 visual, 163-164

visual, characteristics of, 163 in malingerers versus psychotic patients, 163-164

Haloperidol, for agitation and aggression, 796-797

for delirium, in emergency department,

for psychosis, in emergency department, 839-840

Harris v Forklift Systems, Inc. (1993), sexual harrassment, 134-135

Hazelden, abstinence-based model of addiction treatment, 428 Heller v Doe, involuntary hospitalization,

205-206 Hematologic disturbances, with alcohol

use, 355-356 Hepatitis, with injection-drug use, 361

Heritability, of alcoholism, 292 gender differences in, 247 of opiate use, 292

of psychostimulant use, 292 of smoking, 292

of substance use, gender and, 247 HIV disease, with alcohol use, 351

with injection-drug use, 351-352, 365 manifestations of, 366-367 progression of, 366

Home health aides, assault on, 926 Homeless persons, evaluation of, 857 Homelessness, victimization and, in women, 880

Homicide, juvenile, 77-78 sexual, 76-77 risk factors for, 108

Hospital-based psychiatric emergency service(s), advatages and outcome data for, 724 crisis hospitalization, 72-hour beds, 722-

observation in, 23-hour beds, 722

psychiatric emergency department, 719-722

space in, 720 staff in, 720-721

support services in, 721-722

Hospitalization, of child or adolescent, 873-874

of dangerous patient, 53-54 of manic patients, 766 of suicidal patient, 783-784

refusal of, 784

voluntary versus involuntary, as legal issue, 856 Hostile environment, sexual harrassment

and, 131 Harris v Forklift Systems, Inc. (1993),

134-135 Meritor Savings Bank, FSB v Vinson (1986), 134

Hypersexuality, in bipolar II disorder, 520 Hyperthymic temperament, 668 attributes of, 528

criteria for, in bipolar disorder, 695 depression and, 528-531

in atypical depression, 575 mixed states in, 561

rapid cycling in, 594 Hypomania, antidepressant-associated, 519, 526-527

in depressed patient with cyclothymic temperament, 695-696 anxiety disorders and, 571-574

clomipramine-related, obsessive-compulsive disorder and, 569-570

detection of, questions in, 692, 694 in depression, 521-524

key elements in, 692-693 phenomenology of, 691-695 signs and symptoms of, 522-523

temperamental traits in, 694-695 Hypothyroidism, rapid-cycling bipolar disorder and, 588-589

Hysteroid dysphoria, agitated depression versus, 556

bipolar disorder and, 574

Ibogaine, in cocaine addiction, 308 Illicit drug use, community involvement in, 258-261 mortality from, 373

Illness management skills, definition of, 680-681

determinants of, 681 outcome and, 681 psychosocial interventions and, 680–681 Incident report, in stalking, 94–95 Informed consent, in emergency department, competency and, 852–853

exceptions to, 853-854

malpractice and, 7 voluntary hospitalization and, 205 Injection-drug use, drugs of use, 360

infectious syndromes with, 359

medical consequences of, endocarditis, 360–361

fever, 360 hepatitis, 362

infectious and noninfectious, 359

pneumonia, 361 pulmonary, 361 renal disease, 362

renal disease, 362 sexually transmitted diseases, 362, 367 soft-tissue infections, 360

tuberculosis, 361 withdrawal, 362-363

Insanity plea, by criminal defendant, 169–170

Interpersonal and social rhythm therapy (IPSRT), in bipolar disorder, 684–685

Interviewing, psychodynamic, in emergency department, 913–914 Involuntary civil commitment, *Kansas v*

Hendricks, 114, 206-207 Involuntary hospitalization, for suicidal

patient, 784 from emergency department, 859–860 Heller v Doe, 205–206

of mentally ill individuals, 205–206 of mentally retarded individuals, 205– 206

of prisoner, 198

Involutional melancholia, 549

IPSRT (interpersonal and social rhythm therapy), in bipolar disorder, 684–685

Jaffee v Redmond, psychiatrist-patient privilege and, 207–209 Juvenile violence, DSM-IV diagnoses and, 74–76

homicide, categorization of, 78 prevalence of, 77–78

risk factors for, carrying of weapons, 72–73

demographics, 71 gang affiliation, 73–74

assessment for, 74 history of violence, personal and family, 72

sexual, 76-77

violent juvenile and, evaluation of, 78-79 pharmacotherapy for, 79-80 psychotherapy for, 79 treatment of, 79-80

Kansas v. Hendricks, hospitalization of sex offenders and, 114 involuntary civil commitment and, 114, 206–207

Korsakoff syndrome, 806

functional neuroimaging and, 322 Kraepelin, continuum between manic and depressive states, 517–520

depression with flight of ideas in, 550–551

excited depression in, 556 on mania, 536, 550 in children, 629 on melancholia, 549

on mixed states, 535, 550, 561 rapid cycling in, 585–586 temperaments in, 594

temperaments in, 594 unitary position of, 517-520

L-α-Acetylmethadol (LAAM), for opioid dependence, 405–406, 408

LAES(Longitudinal Alcohol Epidemiologic Survey), and gender differences in alcohol abuse and dependence, 242

Lamotrigine, in bipolar disorder, 622 in children, 638 in elderly, for mania, 661

in mixed states, 542 in rapid-cycling bipolar disorder, 598 Legal issue(s), assault on clinician, 860–861

consent to treatment, 852–854 criminal behavior, psychiatric versus criminal cause of, 856–857

duty to protect third party, 49-60 emergency petitions, 854-856

in emergency department, duty to warn and protect endangered party, 858 involuntary hospitalization, 859–860

right to refuse treatment, 854 therapeutic privilege, 854 in emergency psychiatric care, 851–852 involuntary hospitalization, 859–860

patient dumping, 860 threats against life of President of

United States, 859 violence to self or others, assessment of risk for, 857–858

Leuprolide acetate (Lupron), for sex offenders, 122

Level of consciousness, in mental status examination, 822

Levothyroxine, in rapid-cycling bipolar disorder, 597

Life Goals Program, in bipolar disorder, 684–685

Light therapy, in rapid-cycling bipolar disorder, 599

Listening, psychodynamic, in emergency department, 912–913
Lithium carbonate, adverse effects of in

Lithium carbonate, adverse effects of, in elderly, 659

for acute mania, in elderly, 657 for bipolar disorder, noncompliance with, 679

in elderly, for mania, 658–659 psychoeducation and, for compliance, 682

Lithium/lithium carbonate, for bipolar disorder, 619–620 rapid-cycling, resistance to, 596

resistance to, 595-596 for mania, 620

in children and adolescents, 637 in emergency department, 841 for mixed states, 540–542

for substance abuse-bipolar comorbidity, in adolescents, 620

for violent juvenile, 79 response to, in substance abuse, 620 persus valproate, in mania, 620–621

versus valproate, in mania, 620–621 with imipramine, in mixed states, 541 Longitudinal Alcohol Epidemiologic Survey (LAES), and gender

Survey (LAES), and gender differences in alcohol abuse and dependence, 242

Lorazepam, for agitation and aggression, 795–796

for bipolar disorder, agitation in, 750 in emergency psychiatry, for agitated patient, 747

for anxiety syndromes, 772 for delirium, 832–833 for psychosis, 839 for suicidal patient, 783

Major depression, agitated depression and, 556–557

agitation in, 552

as DSM-III term for melancholia, 549-550

in cocaine-dependent patient, 419 unipolar, suicide attempts in, 668–670 Major depressive disorder, characteristics

of, 758–759 in emergency psychiatry, 758–759 treatment of, 763

in substance abuse disorders, 237–238 juvenile violence and, 74–75

Major life activity, psychiatric disability requirements and, interaction with others and, 151–152 performance of work and, 151 personality conflict with supervisor and, 151

Malingered psychosis, 159-172 clinical assessment of, 166-167

delusions and, 161–162 false classification of, consequences of,

hallucinations in, auditory, 161–163

visual, 163-164 in criminal settings, 169-170

indicators of, clinical, 167–168 malingering and, definitions of, 159

of mood disorders, 165–166

purposes of, 160

superimposed, in genuine psychosis, 168 symptom inconsistency in, 160–161 versus schizophrenia, 167–168

Malpractice, childhood sexual abuse and, dissociative identity disorder and, 4–5 false memory of, 3–4

duty to warn third party and, 1-2, 5-6 false memory of childhood sexual abuse and, 3-4

in psychotherapy

American Psychiatric Association Treatment of Psychiatric Disorders and, and standard of care, 7–8

appropriateness of therapy and, 8–9 duty of care and, **1–16**, 11

a generation ago, 1-2 informed consent and, 7, 11

Osheroff suit against Chestnut Lodge, 6–7, 11

restrictions on medical malpractice claims and, 12-13

right to effective treatment and, 6-7 standard of care and, 5-9, 11-12 suicide cases and, 2

therapist sexual misconduct with patients and, 3

Managed care, and standard of care in psychiatric treatment, 11–12 liability, and ERISA, 17–29 mobile psychiatric emergency service

and, 727–728 Mania, affective vulnerability in, 652–653,

661 characterization of, 524

depressive, 535–536, 538 dysphoric, 535–536, 538, 554–555 feigned in malingerer, 166

feigned, in malingerer, 166 full-blown, 519-521

in adolescents, divalproex sodium for, 637

phenomenology of, 633–634 in adults, carbamazepine in, 638 in alcoholism, 613

in children, clinical characteristics of, 631–634

diagnostic criteria for, 629-631 differential diagnosis of, 634-635 incidence of, 631 phenomenology of, 633-634 prevalence of, 631 versus childhood phenomena, 633-634 in mixed states, 543 in old age, acute treatment of, 657, 661age at onset, 651-653 assessment of, 656-657 clinical course of, 651-652 clinical features of, 651 epidemiology of, 650 groupings of, 661 maintenance therapy for, 658 management of, 656-661 nature and management of, 649-665 outcome of, 652-653 Kraepelin on, 536, 550 lithium versus valproate in, 620-621 risk for, in recurrent depression, 520 secondary, 650 disinhibition syndromes and neurologic disorders with, 653-655, 661 social anxiety and, 573-574 types of, in DSM-IV, 649 unipolar, 653 vascular, 656 with panic attacks, 571-573 with poverty of ideas, 554 Manic episode, DSM-IV definition of, 764 in emergency department, pharmacotherapy for, 840-841 symptoms of, 840 major depressive episode with, 765 Manic stupor, description of, 550, 554 Manic syndromes, assessment of, 764-765 clinical presentation of, 764 disorders and substances associated with, 765

management and disposition of, 765-766 Manic-depressive insanity, 552-553 depressive phase of, 553 origin of term, 550 Marijuana, mechanism of action of, 303 Marital dissolution, and death in

alcoholics, 374-375 Mazindol, for cocaine dependence

treatment, 418 Medication compliance, in bipolar disorder, 678-679

in medical setting, 678 with valproate versus lithium, 621

Medroxyprogesterone acetate (MPA, Depo-Provera), for sex offenders, 121-122

Melancholia, agitated form of, 548-549, 551, 557-558 as affective disease, 548

as mood, 548

historical overview of, 548-550, 557-558 mixed states and, 550-552 Melancholia agitans, 548-549, 551, 557-558 Memory, enhancement of, nicotine in, 310 repression mechanism in, lack of support for, 63-64 retrieval cues for, 63 versus repressed memories, 62-63

Men, hyperthymic temperament in, depression and, 528-531

rapid cycling and, 594 Mental health care providers, assault on,

Mental status examination, appearance and behavior in, 822-823 cognitive component of, 823 for anxiety, in emergency department, in dementia, in emergency department,

in psychiatric syndromes, in emergency

room, 822-824 inappropriate affect in, 823 level of consciousness in, 822 perceptual abnormality in, 823

assessment tools for, 823-824 Meritor Savings Banc, FSB v Vinson (1986), sexual harrassment and, 134 Methadone, for opioid dependence,

404-405

in detoxification and maintenance, 408 Methadone maintenance treatment programs (MMTPs), 403

Federal guidelines for, 404 methadone dosage in, 404 for pregnant women, 404

Methamphetamine, prevalence of, 808-809 Methylphenidate, for cocaine dependence treatment, 418

Minnesota Model of addiction treatment, 425, 428

Mixed states, agitated depression as, 556 anticonvulsants versus lithium in, 621 as discrete affective category, 542 as severe bipolar disorder, 543 biologic measures of, 539-540 clinical characteristics of, 536-538 clinical picture and etiologic models of, 535-546

comorbidity with, 537-538 definitions of, 535-536, 554 depression in, diagnostic criteria for, 562 dimensional perspective in, 542-543 elements in, 553-554 family history in, 539 gender and, 537, 539 historical overview of, 550-553 Kraepelin on, 535, 550, 561 mania and depression in, superimposi-

tion of, 543

Mixed states (Continued) mood stabilizers in, 552 obsessive-compulsive disorder in, 538 prevalence of, 538-539 psychotic features in, 538 substance abuse in, 537-538 suicidal ideation in, 537-538 treatment response in, to divalproex sodium, lithium, placebo compared, to electroconvulsive therapy compared with lithium, 541-542 to lamotrigine, 542 to lithium, 540 to lithium-impipramine combination, to valproate versus lithium, 540-541 versus pure manic episodes, 537 MMRPs (methadone maintenance treatment programs), 403 Mobile psychiatric emergency service(s), in gradual emergency, 728-729 in managed care, 727-728 in old and young, 728 in police emergency, 728 in resistant patients, 728 outcomes of, 729-729 role and advantages of, 727, 729 types of, 726-729 Moderation Management, 437 Monoamine oxidase, as marker for alcoholism, 295-296 in smoking-depression linkage, 309-310 Monoamine oxidase inhibitors (MAOIs), rapid-cycling bipolar disorder and, Mood, lability of, predictive of hypomania, 525-526 parallelism with drive and thought, 553-

Mood and anxiety syndromes, in emergency psychiatrcy, 755-777 Mood disorders, delusions in, 742 in emergency department, treatment of, malingering of, depression and, 165 feigned mania, 166 feigned suicide and, 165-166 substance-induced, 649-650 Mood disorder(s), from medications, 842-843 in emergency psychiatry, 756 depressive, 756–764 manic, 764-766 mixed, 765 in medical illness, 841-842 mixed, 765 primary versus medication- or substanceinduced, 842 psychoses in, 741-742

violence in, 794 Mood stabilizers, for dual-diagnosis patient, 342 in combination regimen, in obsessivecompulsive-bipolar disorder comorbidity, 578-579 in mania, in old age, 657 in panic disorder-bipolar comorbidity, with selective serotonin reuptake inhibitors, in social phobia-bipolar comorbidity, 578 Mortality, from alcohol, 372-373 predictors of, 373-375 from illicit drug use, 373 from tobacco, 373 multiple-cause data, 377 Motivational enhancement therapy (MET), in alcoholism treatment, 431-432 Multisystemic therapy (MST), for violent juvenile, 79 Mutual-help programs, definition of, 435-436 Moderation Management, 437 Rational Recovery, 436 Secular Organization for Sobriety, 436 Self Management and Recovery Train-

Naltrexone, for alcohol dependence, 414–415 for detoxification, ultrarapid, 407 for opioid dependence, 406–408, 408 side effects of, 406–407 in opioid detoxification, 403 Naltrindole, in cocaine addiction, 308–309 National Comorbidity Study (NCS), gender differences in substance use disorders, 242 National Household Survey on Drug Abuse (NHSDA), and gender

ing, 437

Women for Sobriety, 435-436

difference in substance use, 242 NCS (National Comorbidity Study), gender differences in substance use disorders, 242 Negligence, sexual misconduct as, 33–34

Negligence, sexual misconduct as, 33–3 Neurobiology, addictive drugs and, 290–291 of addictive disorders, 301–312 of tobacco smoking, 301–312

Neuroimaging, alcohol use and, 316–324 organic mental disorder and, 320, 322–323

cocaine use and, intoxication stage, 324– 325 for treatment response, 222, 224 functional, 305, 314–315 during alcohol abstinence, 322-324 in alcoholism, 320 of cerebral blood flow, 315-316

of cerebral metabolic rate of glucose, 315-316

single-photon emission CT, 315-316 in bipolar disorder, in elderly manic patients, 655-656

structural, 313-314

brain changes in alcoholics in, 320 CT in. 313

limitations of, 314 measurements in, 314

MR imaging in, 314

Neuroleptics, in elderly, for acute mania, 657, 661-662

in rapid-cycling bipolar disorder, 597-598

versus antidepressants, for anxiety, 560-561

Neurologic disorders, alcohol-induced, 356-357

with mania, in old age, 653-655, 661 Neuropsychiatric conditions, juvenile violence and, 76

NHSDA (National Household Survey on Drug Abuse), and gender difference in substance use, 242

Nicotine, biologic response to, gender differences in, 246

mechanism of action for, 303-304 memory enhancement with, 310

Nicotine dependence, comorbidity and, gender differences in, 244

pharmacotherapy for, antidepressants for, 411 as nicotine replacement therapy, 409-

bupropion for, sustained-release, 411

conclusions on, 412

in withdrawal, 408 nicotine gum, 409

nicotine inhaler, 410-411

nicotine nasal spray, 410 transdermal nicotine, 409-410

Nicotine gum, for smoking cessation, 409 Nicotine inhaler, for smoking cessation, 410-411

Nicotine nasal spray, for smoking cessation, 410

Nicotine transdermal, for smoking cessation, 409-410

Nitric-oxide synthase (NOS), for opioid dependence, 408

Noradrenergic dysfunction model, for cocaine withdrawal symptoms, 417 Norepinephrine, in mixed states, 539-540 NOS (nitric-oxide synthase), for opioid

dependence, 408

Nursing staff, assault on, 926

Obsessional following. See Stalking. Obsessive-compulsive disorder (OCD), comorbid with bipolar disorder, 568-570

hypomania in, clomipramine-related, 569-570

in bipolar disorder, 568-570 treatment of, 578-579 in mixed states, 538

OCD. See Obsessive-compulsive disorder

Olanzapine, for depression, psychotic, 750 for schizophrenia, emergency treatment

Oncale v Sundowner Offshore Services (1998), sexual harrassment, 135-136

Opiate use, heritability of, 292

Opiate withdrawal, in emergency services, treatment of, 809-810

Opioid agonists, for substance dependence withdrawal, 401-402

Opioid dependence, pharmacotherapy for, 402-408 conclusions on, 408

endogenous opioid system and, 402-403

in detoxification, 403 in maintenance treatment, 403-404 medications in, 404-408

Opioid intoxication, on emergency service, identification of, 810

Opioidergic agonists, for alcohol dependence, 414-415

Opioids, psychiatric emergencies with, in intoxication, withdrawal, 809

Outcome, illness management skills and,

in dual-diagnosis patient, of integrated treatment, 345-347 of treatment, 339-340

in rapid-cycling bipolar disorder, 599-

of addiction treatment, for adolescents, Oxazepam, for opioid withdrawal, 407

Panic attacks, comorbid with mania,

in bipolar II disorder, 700-701 Panic disorder, bipolar disorder presentation as, 696-697

in anxiety, in emergency department, 844-846

in bipolar disorder, 570, 574 treatment of, 578

in bipolar II disorder, familial-genetic implications of, 570

in emergency psychiatry, 769-770

Panic disorder (Continued) management of, 773 sexual harrassment and, 141

Paranoid patient, in emergency department, psychodynamic interviewing of, 918-919 features of paranoia and, 919-920

patient resistance and, 919 pitfalls in, 919

Paraphilia. See Sexual predators. Patient dumping, from emergency

department, 860

Persecutory hallucinations, 162 Personality disorder. See also Borderline personality disorder (BPD).

sexual harrassment and, 141 violence in, 793-794

PES. See Psychiatric emergency services (PES).

PET (positron-emission tomography), of neural circuitry of addiction, 304-305 Phencyclidine, mechanism of action of, 303

Phobias, in emergency psychiatry, management of, 773-774

Physical abuse, of child or adolescent, emergency department presentation of, 869-870

sequelae of, 869-870

Physicians, assault on, 925 Pneumonia, with injection-drug use, 361

Polysubstance abuse, 289-290 Porphyria, acute intermittent, 738

Positron-emission tomography (PET), of neural circuitry of addiction, 304-305

Postgraduate education and training, in addiction, 481-488

Posttraumatic stress disorder (PTSD), in emergency psychiatry, in women, 878-879

management of, 774-775 in rescue and relief workers, 900 in survivors of disaster, 900 juvenile violence and, 74-75 pharmacotherapy for, 886-887

Prejudice, barrier to effective physician addiction education, 483

Prescribing, in addictive diseases, physician training for, 471-472

Primary care, depression in, 690-691 Prisoners, treatment over objection of, 199-202

Professional standards of care, managed care reduction of, 24 ERISA protection for, 25

Project MATCH, and research on Alcoholics Anonymous, 431-432, 434,

Protective disclosure, of danger, to third party, 54-55, 57

Psychiatric disability, employment, and Americans with Disabilities Act, 147-158. See also Americans with Disabilities Act.

Psychiatric emergency, assessment of, lack

of standards for, 715 Crisis Triage Rating Scale for, 715

Psychiatric emergency services (PES), as training site, benefits of, 941-942 disadvantages of, 942

clinical staff for, 861

components of, 719-730. See also Community psychiatric emergency service(s); Hospital-based emergency service(s). community, 724-730

hospital-based, 719-724

cost of, 719

current state of, reasons for, 715-717

for children, 718-719 for elderly, 718

for substance abuse, 719

goals for, 717-719 continuity of care, 718

diversion to community, 718

in access to care, 717 in assessment, 717

initiation of definitive treatment, 718 specialized care in, 718-719

historical development of, 713-714 improvement of, 730-731

inadequate resources for, 714-715

level 1, 713-734 neglect of, 716-717

training opportunities on, advanced, 951 current, 942-943

triage model in, 713, 715

Psychiatric emergency training programs, clinical decision making in, 945

clinical skills in, 944-945 components of, 946-950

critical incidents in, 950 didactic sessions in, 947

duration of psychiatric emergency service rotation, 946

on-call experience in, 949 orientation in, 947

topics and curriculum in, 944

trainee in, critical incident effect on, 946-947

role of, 946-947 safety of, 947-948

supervision of, 948-950

Psychiatric patients, criminal justice system procedure and, 199-204

Psychiatric syndrome(s), in emergency department, anxiety, 844-847 assessment and management of, 819-849

causes of, medical illnesses, 829 medications, 828

comorbid illnesses in, 820–821 delirium, 825–833 dementia, 830 evaluation of, CT scans in, 825 EEG in, 825 laboratory studies in, 824 medical, 819–820 mental status examination in, 822–824 neurologic examination in, 824 patient interview in, 821–822 physical examination in, 824 mania, 840–841

Psychiatrist-patient privilege, Jaffee v Redmond, 207–209

Psychiatrists, assault on, 925–926 Psychic determinism, 911

Psychodynamic issue(s), in emergency department, antisocial patient, 920–921

general principles, 911–912 in emergency department, 911–922 interviewing technique, 913–914 paranoid patient, 918–920 psychodynamic listening, 912–913 suicidal patient, 914–916 violent or threatening patient, 916–918

Psychoeducation, for sex offenders, 120–121

in bipolar disorder, 679–680 key steps in, 682–683 Psychosis(es), affective, 749–750

phenomenology of, 741–742 cocaine, versus primary psychotic disor-

ders, 808 comorbid, in emergency department,

treatment of, 751

delirium-associated, phenomenology of, 735–737

hallucinogen-induced, treatment of, 745-746

in delusional disorders, 742 in dementia, treatment of, 745

in emergency department, assessment for, 838–839

in children and adolescents, 868–869 from medical condition or substance, 838–839

functional causes of, 868 pharmacologic management of, 839– 840

psychiatric causes of, 868–869 in mood disorders, 741–742 in schizophrenia, phenomenology of,

740–741 medically induced, phenomenology of,

737–738 treatment of, 744–745

phencyclidine-induced, treatment of, 746

phenomenology of, in delusional disorder, 743

in obsessive-compulsive disorder, 743 in posttraumatic stress disorder, 743 substance-induced, in schizophrenia, 812–813

treatment of, 745-747

treatment of, 744-747

withdrawal, treatment of, 746-747

Psychosocial interventions, for bipolar disorder, 675–688

illness management skills in, 680–681 institution of, 679–680 summary of, 680

Psychostimulant use, heritability of, 292 Psychotherapy, in bipolar disorder, 679–680

family focused treatment, 684–685 interpersonal and social rhythm therapy, 684–685

Life Goals Program, 684–685 manual-based, 684

in substance abuse-bipolar morbidity, 623

nature of, 681-685 types of, 683-684

Psychotic disorders, key features of, 736-737

phenomenology and treatment of, in psychiatric emergency service, 735–754

Quetiapine, for schizophrenia, emergency treatment of, 748

Race, effect on mortality, in alcoholism, 378

Racing thoughts, 557–558. See also Crowded thoughts; Flight of ideas. antidepressant effect on, 558

Rapid-cycling bipolar disorder (RCBD), 585–607

anticonvulsants versus lithium in, 621 antidepressant induction of, 590–592 bupropion in, 598 calcium-channel blockers in, 598 carbamazepine in, 596–597 cycle length in, 592 definition of, 586–587 demographic aspects of, 587–588 electroconvulsive therapy in, 599 episode pattern in, 593

familial aspects of, 594-595 gender and, 592-594 Rapid-cycling bipolar disorder (RCBD) (Continued) hypothyroidism and, 588-589 interepisodic period in, 586 lamotrigine in, 598 levothyroxine in, 596-597 light therapy in, 599 lithium resistance in, 595-596 neuroleptics in, 597-598 outcome in, 599-600 phenomenology of, 592 rapid cycling defined in, 585 research considerations in, neurologic, electroencephalographic, neuropsychological, 600-601 proneness to switching, 601 substance abuse relationship to, 600 subtypes of, 593-594 temperament and, 594 valproate in, 596

Rational Recovery (RR), 436 Relapse, in bipolar disorder, 676-677, 682 Repressed memories, de-repressed and mental health, 67-68

false memories of sexual abuse and, 66-67

imagination in, 65-66 retractor studies of, 67 suggestion in, 61-70

case of Princess Diana's bodyguard and, 61-62

de-repressed memories and, 67-68 false memories and, 64-65 ordinary forgetting versus, 63 real memories and, 62-64 University of Washington diary study of, 65-67

University of Washington diary study of, 65-67

Residency programs, emergency medicine, psychiatric emergency skills in, 944 psychiatric, emergency training requirements for, 943

Residency training, in addiction, 477-478 Restlessness, in agitated depression, 559 Restraints, guidelines for, 861

Riggins v Nevada, treatment over objection, 201-202

Right to effective treatment, Osheroff suit against Chestnut Lodge and, 6

Right to refuse treatment, 173-182. See also Treatment over objection. administrative issues in, 177 as best interests standard, 179 clinical aspects of, 174-177 clinical intervention and, 176 clinical management of, 175-176

competency and, assessment of, 177 rights-driven versus treatment-driven

approaches to, 178

countertransferance reactions of hospital staff and, 176

documentation, 180

empiric findings, rights-driven data, 180-181

competency assessments and, 177

treatment-driven data, 180 family intervention and, 176 historical background of, 174

in emergency department, 854 legal issues in, 177-178

compelling treatment, 178 informed consent, 178

proxy decision-making standards, 178-179

psychiatric emergencies, 179-180 reason for, identification of, 175-176 treatment over objection and, Washington v Harper, 199-202

typologies of refusal and, 174-175 Risperidone, for bipolar disorder, 638 for delirium, in emergency department,

for dementia, in emergency department, 836-833

for depression, psychotic, 750 for schizophrenia, emergency treatment

Runaways, child, emergency department handling of, 873

Safety. See also Assault; Violence, in health care setting.

contracting for, with suicidal patient, 782-783

of sexually abused child, 870-871 of trainee, in psychiatric emergency service training program, 947-948

Schizoaffective disorder, diagnosis of, 741 Schizoaffective patient, treatment of, emergency, 747

Schizophrenia, acute decompensation in, treatment of, emergency, 748-749 addictive disorders with, 335 malingered psychosis versus, 167-168 substance abuse in, 812-813 violence in, 793

Seclusion, guidelines for, 861 Secular Organization for Sobriety (SOS), 436

Sedative-hypnotics, withdrawal syndromes with, on emergency service, 810-812 treatment of, 811-812

Selective serotonin re-uptake inhibitors (SSRIs), for alcohol dependence, 415 for anxiety, in emergency department,

for cocaine addiction, 308

for dementia, in emergency department, 836

for sex offenders, 122

for women, borderline personality disorder and post-traumatic stress disorder, 886–887

Self Management and Recovery Training (SMART), 436

Self-help programs. See also Mutual-help programs; Twelve-step programs. definition of, 426

Self-report, in cue reactivity assessment, 452

Sensitization, to substance, 302 Serotonergic agents, for alcohol dependence, 415

Serotonergic dysfunction model, for cocaine withdrawal symptoms, 417 Serotonin, in neurobiology, of addiction,

Sertraline, for post-traumatic stress disorder, rape-related, 887

Sex offender, juvenile, assessment of, 77 profile of, 76–77

Sexual abuse, of child or adolescent, emergency department handling of, 870–871

of patients. See *Therapist-patient sex*. Sexual harassment, claims for, legal basis of, 132

ot, 132 diagnostic considerations in, 140–142 forensic aspects of, 129–145

jury awards for, 129-130 forensic psychiatrist role in, 137-142

evaluation in, incidence of behaviors in, 139–140 issues in, 138–140

psychological testing in, 140 scope of, 137-138

jurisdictional differences and, legal definitions, 132

standards and, Daubert v Frye, 132-133 landmark cases, 134-136

Burlington Industries Inc. v Ellerti, supervisor liability for subordinates, 136

Faragher v Boca, 136 Harris v Forklift Systems, Inc. (1993),

abusive environment, 134–135 Meritor Savings Banc, FSB v Vinson (1986), hostile environment, 134

Oncale v Sundowner Offshore Services (1998), "reasonable person" test and, 135–136

law for, 130-137 consequences and, 131-132

definition of, 130 hostile environment, 131 quid pro quo, 130–131 related claims, 131 legal test for occurrence of, 133–134 "eggshell skull" plaintiff and, 133–134 mental state of perpetrator vs. mental state of victim, 133–134

plaintiff in, hypersensitivity of, 133–134 motives of, 139

pathology of, 138

"reasonable person" criteria and, 139 treatment issues in, confidentiality, 143 erosion of trust, 142–143 manipulation by attorneys, 143 overtreatment and undertreatment,

role of treating psychiatrist, 142–143

therapeutic bias, 142 unclear boundaries, 143 versus traditional torts, 137

Sexual misconduct, therapist, definition of, 33

incidence of, 33 natural history of, 39 professional code of 6

professional code of ethics and, 34 standard of care and, 33–34

Sexual predators, boundaries between criminal behavior and mental illness and, 109–127

evaluation and, comprehensive, 117–118 context and purpose of, 117 of mentally ill offender, 118–119 psychological, 118 psychophysiologic, 118

Hendricks decision, boundaries between criminal behavior and mental illness and, 123–125

sexual predator statutes and, future implications of, 123-124

in-prison treatment and, 123–124 sexual psychopath legislation (1937– 1990) and, 109–111

indeterminate hospitalization and, 111 repeal of, 111

Minnesota, hospitalization for psychopathic personality, 110

Pearson case challenge to, 110 sexual psychopath statutes, definitions in, of mental abnormality, 113 of sexually violent predators, 113

determinate versus indeterminate sentencing and, 112

Washington Legislature preamble to, 112–113

sexual psychopath statutes, 1990s, 114-119

challenge to, 114 effects on psychiatric practice, 116 evaluation and, 116–117

sexually violent predators act, political and social history of, 111-114

treatment of, behavioral, 120 cognitive, 120

Sexual predators (Continued)
goals of, 119
pharmacologic, 121–123
relapse prevention, 121
skills training and psychoeducation,
120–121
Sexuality, in hyperthymic individuals, 530

Sexuality, in hyperthymic individuals, 530 Sexually transmitted diseases, with injection-drug use, 362

Sexually Violent Predator Act (1994), Kansas v Hendricks and, 114, 206–207 mental abnormality issue in, 206–207 sexual predators and, political and social history of, 111–114

Skills training, for sex offenders, 120–121 SMART (Self Management and Recovery

Training), 436 Smoking, cessation of, pharmacotherapy for, 408–411

heritability of, 292 Social phobia, as precursor of mania, 573–574

in bipolar disorder, 567–568, 570, 572–573

treatment of, 578 Social workers, assault on, 926 Somatoform disorders, depression in, 762 SOS (Secular Organization for Sobriety),

436 Specht v Patterson, 111

protections for sex offenders, 110–111 Stalking, clinical risk management of, incident documentation in, 94–95

recognition of dramatic moments in, 96–97 restraining order and, 95

restraining order and, 99 segregation and incarceration in, 96 team approach in, 94 treatment of perpetrator and victim, 95–96

violence risk assessment in, 96

criminalization of, 85 demography of, 86–87 epidemiology of, 86 motivations for, 89 narcissistic linking fan

narcissistic linking fantasy in, 88-89 outcomes in, 90

psychiatric diagnoses and, 87 psychodynamics of, 87–89 pursuits in, 89–90

stalker types and, erotomanic, 86 love obsessional, 86 simple obsessional, 86–87

threatening communication in, 90–91 victim of, emotional consequences in, 90 false victimization syndrome and, 87

model of, 86 violence in, 91–92 affective, 92

data analysis study of, 93-94

homicidal, 92 psychological impact of, 91–92 toward property, 93

Standard of care, in psychotherapy, court appointed expert and, 8–9 court determination of, 9 malpractice and, 5–9, 11–12 schools of therapy and, 9–10 Truth and Responsibility in Mental Health Practices and, 4 sexual misconduct and, 33–34

State ex rel Pearson v Probate Court of Ramsey County, commitment of sexual predators and, 110

Stimulant abuse, bipolarity associated with, 527-528

Stimulant intoxication, treatment of, emergency, 747

Stressors, psychosocial, in bipolar disorder, 675–677

Substance abuse, and emergency psychiatry, **803–817** case example of, 803 dual diagnosis in, 812–814

by child or adolescent, emergency department handling of, 872 by women, victimization and, 880

emergencies in, crisis hospitalization for, 723 in schizophrenia, 812–813

juvenile violence and, 75-76 Substance abuse and dependence,

American Bar Association and, "New Directions in Substance Abuse Policy," 266

DSM-III criteria for, 222–223 DSM-III-R criteria for, 223–225 genetics of, 297–298

and basis of vulnerability, 293, 297 animals studies of, 293–294

heritability in, 291–292 heterogeneity in, 292–283 human studies of, 294–297

alcohol metabolism and flushing response, 296–297 alcohol sensitivity, 295

clinical subgroups in, 294–295 electrophysiologic markers in alcoholism, 295

neurochemical markers, 295–296 research in, information misuse and,

whole-genome linkage scans in, 297 medical consequences of, 351–370 for alcohol, 352–358

for cocaine, 363–367 for injection drug, 358–363

moral theory of, 266 vs. dependence, 227–228

Substance abuse disorders. See also Alcohol abuse/dependence.

and bipolar comorbidity, 609-627 in mixed states, 537-538 prevalence of, 609 violence in, 813-814 Substance abuse disorder(s)-bipolar disorder comorbidity, alcoholism, primary versus secondary, 618 clinical course of, 618-619 diagnostic issues in, 616-618 differential diagnosis of depression, mania versus depression, 616-617 subtyping bipolar disorder, 617 symptom overlap, 616-617 use of structured or semistructured interviews, 617-618 drug abuse, 611-612 pharmacotherapy for, 619-622 prevalence of, 609-613 in non-treatment-seeking individuals, 611-613 in treatment-seeking individuals, 613psychotherapeutic approach to, 623 rapid-cycling in, 600 stimulant abuse, 527-528 theories for, 613, 615-616 bidirectionality, 615 genetic basis, 615 intoxication mimic of depression and mania, 613, 615 neuronal sensitization in withdrawal, 615-616 self-medication, 615 Substance abuse disorders-psychiatric comorbidity, 609-610 Substance abuse services, cost-effectiveness analysis of, 386-392 analytic approach to, 391-392 average service costs in, 392-393 baseline program in, 388 contact bias in, 399 context in, 386 cost-effectiveness trade-offs with patient types, 393-395 definitions in, of costs, 389-390 of outcome, 388-399 effectiveness in, 392 lack of control group in, 399 policy and practice implications of, 397-398 policy questions in, 387 results of, 392-397 service intensity in, 393 statistical adjustment for patient characteristics, 390-391 treatment approaches studied in, 387

treatment types and, 395-396

cost-effectiveness of, 385-400

computation of, 398

social costs incurred and saved with, Substance use and dependence, adverse effect of, on affective disorders, 619 nosology of, DSM-IV and, 335-336 Substance use disorders, course of illness in, gender differences in, 247-248 DSM-IV and, categories of, 279-280 dependence vs. abuse in, 280 diagnostic criteria in, 280 epidemiology of, gender differences in, 241-242 gender differences in, 241-252 in adolescents, assessment of, 283-284 clinical picture, 278-279 developmentally accepted normal use in, 277 epidemiology of, 275-277 intervention and prevention of, 282nosology and, 279-280 psychiatric comorbidity with, 281-282 subtypes and, 280 transition from use to abuse, 277-278 treatment of, 284-286 prognostic factors and, 284 program environment and services and, 285-286 staff characteristics and, 285 time in, 285 treatment of, gender differences in, 248-Substance-abuse disorders, 336 Substance-dependence disorder, 336 Substance-induced disorder, 336 in dual-diagnosis patient, assessment of, 337-338 medication guidelines for, 340-343 stabilization of, 338-340 Substance-induced psychosis(es), amphetamine, 738-739 cocaine, 739 hallucinogen ketamine, 739 phencyclidine, 739 phenomenology of, 738-740 withdrawal, alcohol, 739-740 benzodiazepine, 739 Substance-related disorders, neuroimaging of, structural and functional, 313-329 Substance-use disorders, and emergency psychiatry, alcohol intoxication and withdrawal, 805-807 cocaine intoxication, 807-809 opioid overdose, 809-810 prevalence of, 804-805 Suicidal behavior, in bipolar I disorder, 668-670

in bipolar II disorder, 667-673

self-blame and, 671

Suicidal ideation, 780–784
crisis hospitalization for, 723
in alcohol intoxication, 807
in antisocial patient, 921
in emergency department, psychodynamic issues with, 914–916
in mixed states, 537–538
with substance use. 813

Suicidal patient, comorbid mental illnesses in, 782

emergency room assessment of, 779–787 in emergency department, assessment of, 780–784

psychodynamic, 914–916 contracting for safety with, 782–783 treatment setting for, 783–784

Suicide. See also Suicidal patient. attempted, in bipolar II, bipolar II, and unipolar depressions, 669–670 in bipolar II versus bipolar I disorder, 671

completed, high risk for, in bipolar II disorder, 670-672

in bipolar I, bipolar II, and unipolar depression, 669–670

epidemiology of, 779–781 feigned, in malingerer, 165–166 in alcoholism, 374–375

in bipolar II disorder, comorbidity and, 671

social prominence and creativity and,

liability of utilization reviewers for, ERISA managed care plans and, 21-23

Hughes v Blue Cross of Northern California, 22–23

medical necessity and, 22–23 Wilson v Blue Cross of Southern California, 21–23

methods in, 780 prediction of, 784-786

association with psychiatric illness, 785

communication of intent and, 784–786 frequency of medical contacts and, 785

prior attempts, 785

risk for, emergency department assessment of, 857–858

in children and adolescents, 866 threatened or attempted, in children and adolescents, 866

in women, 882

Survivors of disaster, as group, versus individuals in, 897–898 children, 905

common experiences of, 898–899 debriefings of, 906–907 intervention for, principles of, 903–904 psychoeducation, 906 therapeutic goals in, 904–905 with children, 905 with relief workers, 906 therapeutic approaches for, 897–910

Tarasoff v Regents of University of California, duty to warn third party and, 1-2, 5-6

Temperament cyclothymic. See Cyclothymic tempera-

hyperthymic. See *Hyperthymic tempera*ment.

Testosterone reduction therapy, for sexual offenders, 121–122

Therapeutic privilege, in emergency department, 854

Therapist sexual misconduct, therapists at risk for, 43–44

Therapist-patient sex. See also Sexual misconduct.

boundary guidelines for psychotherapy, 31–32

principles underlying, 32–33 boundary violations and, Exploitation Index of warning indicators and, 44–45

identification and prevention of, 44-45 progression of, 39-43

cessation trauma and, with termination of therapy, 42–43 civil-criminal penalties for, 34–35

countertransference and, clinical vignette, 40–42

erotic, 35–36 overidentification and rescue, 38 reparenting attempts, 38–39

from boundary violations to sexual misconduct, 31-47

legal and ethical consequences of, 35 post-termination, 34

prevention of, 44–45 professional disciplinary action for, 35 therapists at risk for, 43–44

transference and, 35 transference and countertransference

and, 35-39 transference themes in, common, 37-39

undue influence model in, 36 Threat, direct, meaning of, in Americans with Disabilities Act, 148, 154–155

Threatening communication, by stalkers, 91–92

instrumental, 91-92

Threatening patient, in emergency department, evaluation of, 916–918 Threats against life of President of United

States, 859

Thyroid function tests, in mixed states, 540 Tobacco smoking. See also Nicotine dependence; Smoking cessation. antidepressant properties of, 309-310 effects of, 408

neurobiology of, 301-312, 309-310 Tobacco use, mortality from, 373

in alcoholism, 375-376 Tolerance, molecular mechanisms in, 307 Training issues in emergency psychiatry,

941-954 Transference, in therapist-patient sex,

35-39 Trauma, in survivors of disaster, adaptation phase in, 900 disruption or displacement, 902-903 response phase in, 899-900 terror or horror, 899-900 traumatic bereavement, 900-902

to women, emergency service assessment of, 882

Traumatization, of survivors of disaster, 898-899

Treatment over objection. See also Right to refuse treatment.

of pretrial detainee, 201-202 of prisoner, 199-202

Riggins v Nevada, 201-202 Washington v Harper, 199-202

Tricyclic antidepressants, versus selective serotonin reuptake inhibitors, in rapid-cycling bipolar disorder, 591 Tuberculosis, with injection-drug use, 361,

Twelve-step facilitation (TSF) therapy, in alcoholism treatment, 431, 434-435 what psychiatrists should know, 434-435

Twelve-step programs. See also Alcoholics Anonymous (AA).

definition of, 426-427 drop-out rate in, 430

growth and spread of, 428-430

origin of, 427

problems psychiatrists must address, 437-440

bad advice to psychiatric patients, 439-440 religious/spiritual aspect of, 437-438

scientific issue, 438 unhealthy dependence on, 438-439 research on, 430-434

Vaillant's prospective study of, 427 what psychiatrists should know, 427-430

Undergraduate medical education, in addiction, detection and prevention of relapse, 477 exposure to experiential components of, 473-474

for complications of, 476-477 patient history for patients at risk, 474 physical examination in detection of, 476

prevention strategies for, 475 training in diagnosis of, 474 withdrawal management in, 475

United States Supreme Court and Psychiatry in 1990s, 197-211

competence to plead guilty or waive right to counsel, Godinez v Moran, 203-204

involuntary civil commitment and, Kansas v Hendricks, 206-207

involuntary hospitalization, Heller v Doe, 205-206

psychotherapy-patient privilege, laffee v Redmond, 207-209

retention of insanity acquittee, Foucha v Louisiana, 114, 202-203

treatment over objection and, 199-202 Riggins v Nevada, 201-202 Washington v Harper, 199-200

voluntary hospitalization, competency for, 204-205

Zinermon v Burch, 204-205

Valproate, compliance with, versus lithium,

in bipolar disorder, noncompliance with, 678-679

in elderly, for mania, 659-660 in acute mania, 657 in maintenance therapy, 658

in manic episode, 766 in rapid-cycling bipolar disorder, 596

with lithium, 596 versus lithium, in mixed states, 540-541

Valproate sodium, for mania, in emergency department, 841 Values, cultural and war on drugs, 265

and national policy, 265-267 Victimization, in drug trading, 260-261

of women, and assessment and treatment in emergency setting, 875-896 assessment of, 881-883 impact on health service use, 876

prevalence of, 875-876 sequelae of, 876-877 sexual, 877

with psychiatric-substance abuse comorbidity, 245

Violence. See also Assault.

and mental disorders, epidemiology of, 790-791

causes of, 789

in contemporary society, 924 in health care settings, 924-930 Violence (Continued)

in substance-abuse disorders, 790-791, 813-814

juvenile, 71-83. See also Juvenile violence.

risk factors for, 108 stalker, 91-92, 96-97

to self or others, assessment of risk for, 857–858

workplace, 101–108. See also Workplace violence.

Violent patient, child or adolescent, 867 clinician education for handling, 933–934 in emergency department, assessment of, 791–792

> differential diagnosis of, 792–795 for anxiety disorders, 794–795 for comorbid substance use, 790–792

for mood disorders, 794 for personality disorders, 793–794

for schizophrenia, 793 psychodynamic issues with, 916–917

case example of, 917–918 safety precautions with, 791 transient *versus* persistent violence and, 792

treatment of, 795-798

in emergency setting, therapies for, 789 in the emergency setting, **789–801** persistent *versus* transient, 792

Vitek v Jones, involuntary hospitalization from prison, 198

Voluntary psychiatric hospitalization, Zinermon v Burch, 204–205

War on drugs, as externalization of internal problem, 263–265 cultural beliefs and national values in, 264–265

Washington v Harper, treatment over objection, 199–202

Wernicke encephalopathy, 357

structural neuroimaging and, 320, 322 Wernicke's encephalopathy, presentation of, 806

Withdrawal, alcohol, 357, 805–807 psychosis in, 739–740

cocaine, 416-417, 421

neuroimaging of, 324-325 drug and alcohol, in DSM-III, 223

in DSM-III-R, 225 in DSM-IV, 228

in ICD-10, 227 injection-drug, 362-363

pharmacotherapy for, 341

Women, agitated depression in, 561 alcohol use by, 805 bipolar disorder in, rapid-cycling, 588, 592, 601

bipolar illness in, 593-594

hypothyroidism in, 588-589 mania in, in old age, 650

mixed states in, 537–539

use of emergency services by, for acute distress disorder, 877–878

for borderline personality disorder, 879

for post-traumatic stress disorder, 878– 879

victimization of, 875–896. See also Victimization, of women.

assessment in emergency service, 881–883

evidence collection and, 883-884

interation with emergency service provider, 887–889

risk factors for, 879-880

treatment of, 883-885

pharmacotherapy for, 886-887 triage in, 884

Women for Sobriety, 435-436

Workplace violence, clinician's role in, 101-108

advisory to corporate, 105–106 homicidal statements and, 102–105 in college workplace, 106–107 loyalties and, contradictory, 101 prediction of, 104–105 privacy and confidentiality issues and,

105 termination issues and, 107–108

threats in, denial of, 106 employee profile in, 102

homicidal statements in, 102–105 blue collar milieu and, 103 meeting with employee, 103–104 off-site, 103

perception of observers and, 103 workplace killer and, 108

Youngberg v Romeo, involuntary admission of retarded man to state school, 8, 198–199

Zinermon v Burch, competence for voluntary psychiatric hospitalization, 204–205

Ziprasidone, for agitation and aggression, 797–798

for schizophrenia, emergency treatment of, 749

